Program
Sunday, Nov. 4
Registration
2-7:30 p.m.
Welcome: A Conversation with the Course Directors
4-4:30 p.m.
George D. Demetri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Susan Band Horwitz, PhD, Albert Einstein College of Medicine, Bronx, New York
Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
Workshop Alumni Panel: From Bench to Bedside – How to Translate a Basic Science Study to the Clinic
4:30-6 p.m.
Aime T. Franco, PhD, University of Arkansas for Medical Sciences, Little Rock, Arkansas
Diwakar R. Pattabiraman, PhD, Geisel School of Medicine, Dartmouth College/Norris Cotton Cancer Center, Lebanon, New Hampshire
Goli Samimi, PhD, National Cancer Institute, Rockville, Maryland
Monique Dail, PhD, Genentech, South San Francisco, California
Opening Keynote Presentation
6-7 p.m.
Preclinical cancer target validation: Avoiding common pitfalls
William G. Kaelin, Jr., MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Introductions: Workshop Participants
7-7:30 p.m.
George D. Demetri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Susan Band Horwitz, PhD, Albert Einstein College of Medicine, Bronx, New York
Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
Opening Reception and Dinner
7:30-9 p.m.
Top of page
Monday, Nov. 5
Continental Breakfast
7-8 a.m.
Pre-Test (required)
8-8:30 a.m.
Introduction to Cancer Medicine and Diagnostics
8:30-9:45 a.m.
Overview
George D. Demetri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Overview of pathology and molecular tools in diagnostics
Lynette M. Sholl, MD, Brigham and Women's Hospital, Boston, Massachusetts
Break
9:45-10 a.m.
Introduction to Cancer Medicine and Diagnostics (continued)
10-11:30 a.m.
Cancer imaging: The role of imaging in oncology
Lawrence H. Schwartz, MD, Columbia University Medical Center, New York, New York
EGFR mutant lung cancer: From clinic to bench to back to clinic
Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
Panel Discussion and Questions: Personalized Cancer Medicine and What It Means in the Clinic
Buffet Lunch
11:30 a.m.-12:30 p.m.
Offsite Laboratory Visits
12:30-5 p.m.
Dana-Farber Cancer Institute
*Transportation will be provided.
Surgical Pathology Laboratory tour and discussion
Diagnostic Radiology Laboratory tour and discussion
*Workshop attendees visit both laboratories during the time allotted.
Group Buffet Dinner
5-6 p.m.
Study Design Track: Project Meeting #1
Those who are in the Project Meeting will miss the One-on-One Meetings.
5:45-7:15 p.m.
One-on-One Meetings ("Office Hours")
6-7 p.m.
How Treatment Decisions Are Made
7:15-8:15 p.m.
George D. Demetri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
Lynette M. Sholl, MD, Brigham and Women's Hospital, Boston, Massachusetts
Top of page
Tuesday, Nov. 6
Continental Breakfast
7-8 a.m.
The
Environment of Clinical Investigations
8-10:30 a.m.
Clinical research: An overview
Peter C. Adamson, MD, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
Human subjects considerations in translational research
Mark E. Robson, MD, Memorial Sloan Kettering Cancer Center, New York, New York
Protection of human research participants
Alison Bateman-House, PhD, MPH, MA, NYU School of Medicine, New York, New York
Why quantitative reasoning is important in translational cancer research
Mimi Kim, ScD, Albert Einstein College of Medicine, New York, New York
Panel Discussion
Break / Group Photo
10:30-11:30 a.m.
Offsite IRB Observational Visit
11:30 a.m.-2 p.m.
Dana-Farber Cancer Institute
*Transportation will be provided.
Participants observe a live Institutional Review Board (IRB) session in order to gain insights into issues of protection of human subjects that are at the heart of translational research.
Lunch / Overview of IRB
George D. Demetri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Observation of Live IRB Session
Panel Discussion and Questions on Live IRB Session
Orientation / Questions for Cancer Patient Clinic Visits
2-2:30 p.m.
George D. Demetri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
Free Time
2:30-4 p.m.
Study Design Track: Project Meeting #2
3-4:30 p.m.
One-on-One Meetings (”Office Hours”)
4-5:30 p.m.
Group Buffet Dinner
5:30-6:30 p.m.
Small
Group Discussion Sessions with Clinician and Patient
6:30-8 p.m.
Each small group consists of a
clinician, a patient, and approximately 10-15 workshop attendees. This
provides a comfortable environment and encourages interaction. We ask
doctors to share their perspectives as clinicians and researchers and
patients to speak about whatever they feel most comfortable sharing
regarding their experiences as patients/clinical trial participants.
Top of page
Wednesday, Nov. 7
Continental Breakfast
7:45-8:45 a.m.
Offsite Patient Clinic Visits
8:45 a.m.-12 p.m.
Dana-Farber Cancer Institute
Massachusetts General Hospital
*Transportation will be provided.
Buffet Lunch
12-1 p.m.
The Research and Development Process
1-3:45 p.m.
Taxol, tubulin, and tumors: A story of drug development
Susan Band Horwitz, PhD, Albert Einstein Medical College, Bronx, New York
Title to be announced
Jennifer Guerriero, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
Developing new approaches to difficult drug cancer targets
Nathanael S. Gray, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
The emerging role of CAR T-cells and other engineered cell therapies for the treatment of cancer
Caron A. Jacobson, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Panel Discussion and Questions: Research and Development
Break
3:45-4:15 p.m.
Interactive Lab and Demo-cBioPortal: Cancer Genomics and Translational Research
4:15-6:15 p.m.
The cBioPortal for cancer genomics
Nikolaus Schultz, PhD, Memorial Sloan Kettering Cancer Center, New York, New York
Tali Mazor, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
Study Design Track: Project Meeting #3
4:15-6:15 p.m.
Those who are in the meeting will not participate in the cBioPortal session.
Evening on Own
6:15 p.m.-
Top of page
Thursday, Nov. 8
Continental Breakfast
7:45-8:45 a.m.
Offsite Patient Clinic Visits
8:45 a.m.-12 p.m.
Dana-Farber Cancer Institute
Massachusetts General Hospital
*Transportation will be provided.
Buffet Lunch
12-1 p.m.
Targeted Medicine
1-3:30 p.m.
Development of combinatorial strategies to address PARP inhibitor resistance
Geoffrey I. Shapiro, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
Genomic analysis of cell-free plasma DNA
Geoffrey R. Oxnard, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Regulatory science: What are the issues?
Michael E. Menefee, MD, Food and Drug Administration, Silver Spring, Maryland
Biomarkers and molecular diagnostics: The problem of patient selection
Maureen Cronin, PhD, Celgene Corporation, San Francisco, California
Panel Discussion and Questions: Targeted Medicine
Break
3:30-4 p.m.
Panel Discussion on Entrepreneurship in Translational Research
4-5:30 p.m.
Christoph Lengauer, PhD, Celsius Therapeutics, Cambridge, Massachusetts
John Maraganore, PhD, MS, Alnylam Pharmaceuticals, Cambridge, Massachusetts
Robert T. Nelsen, MBA, Arch Venture Partners, Seattle, Washington
Mike Powell, PhD, Sofinnova Ventures, Menlo Park, California
Dinner
5:30-6:30 p.m.
Special Seminar and Group Discussion: Unleashing the Power of Immune System – Focus on Translational Immunology
6:30-8 p.m.
From basic science to cancer immunotherapy: T cell-mediated anti-tumor immunity
Kai W. Wucherpfennig, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
Title to be announced
Patrick Ott, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
Top of page
Friday, Nov. 9
Continental Breakfast
7-8 a.m.
Translating Differently
8-10:45 a.m.
Cancer health disparities
Timothy R. Rebbeck, PhD, Harvard School of Public Health, Boston, Massachusetts
Precision head and neck cancer medicine
Jennifer R. Grandis, MD, University of California, San Francisco, California
Identifying active drug regimens using functional precision medicine
Patrick D. Bhola, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
Antibody-drug conjugates and monoclonal antibody bioengineering
Robert Phillips, PhD, Daiichi-Sankyo, Basking Ridge, New Jersey
Closing Remarks
10:45-11 a.m.
George D. Demetri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Susan Band Horwitz, PhD, Albert Einstein College of Medicine, Bronx, New York
Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
Post-Test / Evaluation
11 a.m.-12 p.m.
Attendee Departure
12:15 p.m.
Top of page
